Strategies and New Developments in the Management of Bacterial Meningitis

Infectious Disease Clinics of North America

Volumn 23, Issue 4, 2009, Pages 925-943

  Miranda, Justine ^a   Tunkel, Allan R ^b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b MONMOUTH MEDICAL CENTER   (United States)

Author keywords

Antimicrobial resistance; Antimicrobial therapy; Bacterial meningitis; Blood brain barrier; Cerebrospinal fluid

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; DAPTOMYCIN; DEXAMETHASONE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; ORITAVANCIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL GROWTH; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; BLOOD BRAIN BARRIER; BLOOD PH; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID PH; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPIDEMIC MENINGITIS; GRAM NEGATIVE INFECTION; GROUP B STREPTOCOCCAL MENINGITIS; HUMAN; IONIZATION; LIPID SOLUBILITY; LISTERIOSIS; LIVER TOXICITY; LOADING DRUG DOSE; MENINGITIS; MOLECULAR WEIGHT; NEUROTOXICITY; NONHUMAN; PNEUMOCOCCAL MENINGITIS; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BLOOD-BRAIN BARRIER; CEREBROSPINAL FLUID; DRUG RESISTANCE, BACTERIAL; HUMANS; MENINGITIS, BACTERIAL;

EID: 70350714124     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.06.014     Document Type: Review

References (106)

1. Tunkel A.R. Bacterial meningitis (2001), Lippincott Williams & Wilkins, Philadelphia
2. Casado-Flores J., Aristegui J., de Liria C.R., et al. Clinical data and factors associated with poor outcome in pneumococcal meningitis. Eur J Pediatr 165 (2006) 285-289
3. van de Beek D., de Gans J., Tunkel A.R., et al. Community-acquired bacterial meningitis in adults. N Engl J Med 354 (2006) 44-53
4. Makwana N., and Riordan F.A. Bacterial meningitis: the impact of vaccination. CNS Drugs 21 (2007) 355-366
5. Adams W.G., Deaver K.A., Cochi S.L., et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 269 (1993) 221-226
6. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 (2003) 137-146
7. Swartz M. Bacterial meningitis: a view of the past 90 years. N Engl J Med 351 (2004) 1826-1828
8. Tzanakaki G., and Mastrantonio P. Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region. Int J Antimicrob Agents 29 (2007) 621-629
9. Nigrovic L.E., Kupperman N., and Malley R. Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med 15 (2008) 522-528
10. Centers for Disease Control and Prevention (CDC). Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae: Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep 56 (2007) 1077-1080
11. Sinner S.W., and Tunkel A.R. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin North Am 18 (2004) 581-602
12. Tunkel A.R., and Scheld W.M. Applications of therapy in animal models to bacterial infection in human disease. Infect Dis Clin North Am 3 (1989) 441-459
13. Andes D.R., and Craig W.A. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 13 (1999) 595-618
14. Lutsar I., McCracken Jr. G.H., and Friedland I.R. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 27 (1998) 1117-1129
15. Spector R. Advance in understanding the pharmacology of agents used to treat bacterial meningitis. Pharmacology 41 (1990) 113-118
16. Quagliarello V.J., Long W.J., and Scheld W.M. Morphologic alterations of the blood brain barrier with experimental meningitis in the rat. J Clin Invest 77 (1986) 1084-1095
17. Paris M.M., Hickey S.M., Uscher M.I., et al. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 38 (1994) 1320-1324
18. Cabellos C., Martinez-Lacasa J., Martos A., et al. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Antimicrob Agents Chemother 39 (1995) 2158-2160
19. Scheld W.M., and Brodeur J.P. Effect of methylprednisolone on entry of ampicillin and gentamicin into cerebrospinal fluid in experimental pneumococcal and Escherichia coli meningitis. Antimicrob Agents Chemother 23 (1983) 108-112
20. Chowdhury M.H., and Tunkel A.R. Antibacterial agents in infections of the central nervous system. Infect Dis Clin North Am 14 (2000) 391-408
21. Dragan R., Velghe L., Rodda J.L., et al. Penetration of meropenem into cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother 34 (1994) 175-179
22. Schmidt T., Floula J., and Täuber M.G. Clarithromycin lacks bactericidal activity in cerebrospinal fluid in experimental pneumococcal meningitis. J Antimicrob Chemother 32 (1993) 627-632
23. Flatz L., Cottagnoud M., Kuhn F., et al. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci. J Antimicrob Chemother 53 (2004) 305-310
24. Kuhn F., Cottagnoud M., Acosta F., et al. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro. Antimicrob Agents Chemother 47 (2003) 2487-2491
25. Steinberg E., Overturf G.D., Wilkins J., et al. Failure of cefamandole in treatment of meningitis due to Haemophilus influenzae type b. J Infect Dis 137 (1978) S180-S186
26. Syriopoulou V.P., Scheifele D.W., Sack C.M., et al. Effect of inoculum size on the susceptibility of Haemophilus influenzae b to beta-lactam antibiotics. Antimicrob Agents Chemother 16 (1979) 510-513
27. Kasiakou S.K., Sermaides G.J., Michalopoulos A., et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomized controlled trials. Lancet Infect Dis 5 (2005) 581-589
28. Lutsar I., Ahmed A., Friedland I.R., et al. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 41 (1997) 2414-2417
29. Ahmed A., Paris M.M., Trujillo M., et al. Once-daily gentamicin therapy for experimental Escherichia coli meningitis. Antimicrob Agents Chemother 41 (1997) 49-53
30. Rodriguez-Cerrato V., McCoid C.C., Michelow I.C., et al. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother 45 (2001) 3092-3097
31. Kim Y.S., Liu Q., Chow L.L., et al. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 41 (1997) 1186-1189
32. McCracken G. Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis. Clin Infect Dis 31 Suppl 2 (2000) S45-S50
33. Tunkel A.R., Hartman B.J., Kaplan S.L., et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 (2004) 1267-1284
34. Peltola H., Anttila M., Renkonen O.V., et al. Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Lancet 1 (1989) 1281-1287
35. Lebel M.H., Hoyt M.J., and McCracken Jr. G.H. Comparative efficacy of ceftriaxone and cefuroxime for treatment of bacterial meningitis. J Pediatr 114 (1989) 1049-1054
36. Nathan N., Borel T., Djibo A., et al. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomized non-inferiority study. Lancet 366 (2005) 308-313
37. Norby S.R. Role of cephalosporins in the treatment of bacterial meningitis in adults: overview with special emphasis on ceftazidime. Am J Med 79 (1985) 56-61
38. Rodriguez W.J., Khamn W.N., Cocchetto D.M., et al. Treatment of Pseudomonas meningitis with ceftazidime with or without concurrent therapy. Pediatr Infect Dis J 9 (1990) 83-87
39. Mizen L., Woodnutt G., Kernutt I., et al. Simulation of human serum pharmacokinetics of ticarcillin-clavulanic acid and ceftazidime in rabbits, and efficacy against experimental Klebsiella pneumoniae meningitis. Antimicrob Agents Chemother 33 (1989) 693-699
40. Huang C.R., Lu C.H., Chuang Y.C., et al. Adult Pseudomonas aeruginosa meningitis: high incidence of underlying medical and/or postneurosurgical conditions and high mortality rate. Jpn J Infect Dis 60 (2007) 397-399
41. Tsai Y.H., Bies M., Leitner F., et al. Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats. Antimicrob Agents Chemother 34 (1990) 733-738
42. Rousseau J.M., Soullie B., Villevieille T., et al. Efficiency of cefepime in postoperative meningitis attributable to Enterobacter aerogenes. [letter]. J Trauma 50 (2001) 971
43. Gerber C.M., Cottagnoud M., Neftel K., et al. Evaluation of cefepime alone and in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. J Antimicrob Chemother 45 (2000) 63-68
44. Cottagnoud P., Acosta F., Cottagnoud M., et al. Cefepime is efficacious against penicillin- and quinolone-resistant pneumococci in experimental meningitis. J Antimicrob Chemother 49 (2002) 327-330
45. Lodise Jr. T.P., Nau R., Kinzig M., et al. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 58 (2007) 445-452
46. Saez-Llorens X., and O'Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J 20 (2001) 356-361
47. Wong V.K., Wright Jr. H.T., Ross L.A., et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 10 (1991) 122-125
48. Zhanel G.G., Wiebe R., Dilay L., et al. Comparative review of the carbapenems. Drugs 67 (2007) 1027-1052
49. Cottagnoud P., Pfister M., Cottagnoud M., et al. Activities of ertapenem, a new long acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 47 (2003) 1943-1947
50. Norrby S.R. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother 45 (2000) 5-7
51. Schmutzhard E., Williams K.J., Vukmirovits G., et al. A randomized comparison of meropenem with cefotaxime and ceftriaxone for the treatment of bacterial meningitis in adults: meropenem meningitis study group. J Antimicrob Chemother 36 Suppl A (1995) 85-97
52. Klugman K.P., and Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 39 (1995) 1140-1146
53. Odio C.M., Puig J.R., Feris J.M., et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J 18 (1999) 581-590
54. Maiques J.M., Domenech A., Cabellos C., et al. Evaluation of antimicrobial regimens in a guinea-pig model of meningitis caused by Pseudomonas aeruginosa. Microbes Infect 9 (2007) 435-441
55. Buckingham S.C., Davis Y., and English B.K. Pneumococcal susceptibility to meropenem in a mid-south children's hospital. South Med J 95 (2002) 1293-1296
56. Kim S.W., Jim J.H., Kang S.J., et al. Therapeutic efficacy of meropenem for treatment of experimental penicillin-resistant pneumococcal meningitis. J Korean Med Sci 19 (2004) 21-26
57. Force E., Taberner F., Cabellos C., et al. Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis. Eur J Clin Microbiol Infect Dis 27 (2008) 685-690
58. Friedland I.R., Paris M., Ehrett S., et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 43 (1999) 2372-2375
59. Cottagnoud P., Cottagnoud M., and Täuber M.G. Vancomycin acts synergistically with gentamicin against penicillin-resistant pneumococci by increasing the intracellular penetration of gentamicin. Antimicrob Agents Chemother 47 (2003) 144-147
60. Martinez-Lacasa J., Cabellos C., Martos A., et al. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 49 (2002) 507-513
61. Viladrich P.F., Gudiol F., Linares J., et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 35 (1991) 2467-2472
62. Klugman K.P., Friedland I.R., and Bradley J.S. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 39 (1995) 1988-1992
63. Ahmed A., Jafri H., Lutsar I., et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 43 (1999) 876-881
64. Ricard J.D., Wolff M., Lacherade J.C., et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 44 (2007) 250-255
65. Novak R., Henriques B., Charpentier E., et al. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 399 (1999) 590-593
66. Rodriguez C.A., Atkinson R., Bitar W., et al. Tolerance to vancomycin in pneumococci: detection with a molecular marker and assessment of clinical impact. J Infect Dis 190 (2004) 1481-1487
67. McCullers J.A., and English B.K. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 181 (2000) 369-373
68. Gerber J., Smirnov A., Wellmer A., et al. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 45 (2001) 2169-2172
69. Cabellos C., Fernandez A., and Maiques J.M. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 47 (2003) 1907-1911
70. Cabellos A.F., Tubau F., Maiques J.M., et al. Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 55 (2005) 78-83
71. Kralinsky K., Lako J., Dluhollucky S., et al. Nosocomial staphylococcal meningitis in neonates successfully treated with intraventricular teicoplanin. Chemotherapy 45 (1999) 313-314
72. Arda B., Yamazhan T., Sipahi O.R., et al. Meningitis due to methicillin-resistant Staphylococcus aureus (MRSA): Review of 10 cases. Int J Antimicrob Agents 25 (2005) 414-418
73. Sipahi O.R., Arda B., Yurtseven T., et al. Vancomycin versus teicoplanin in the therapy of experimental methicillin-resistant Staphylococcus aureus (MRSA) meningitis. Int J Antimicrob Agents 26 (2005) 412-415
74. Suntur B.M., Yurtseven T., Sipahi O.R., et al. Rifampicin + ceftriaxone versus vancomycin + ceftriaxone in the treatment of penicillin- and cephalosporin-resistant pneumococcal meningitis in an experimental rabbit model. Int J Antimicrob Agents 26 (2005) 258-260
75. Lee H., Song J.H., Kim S.W., et al. Evaluation of a triple drug combination for treatment of experimental multidrug-resistant pneumococcal meningitis. Int J Antimicrob Agents 23 (2004) 307-310
76. Nau R., Wellmer A., Soto A., et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis 179 (1999) 1557-1560
77. Bottcher T., Gerber J., Wellmer A., et al. Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J Infect Dis 181 (2000) 2095-2098
78. Schonwald S., Geus I., Lisic M., et al. Ciprofloxacin in the treatment of gram-negative bacillary meningitis. Am J Med 87 (1989) 248S-249S
79. Wong-Beringer A., Beringer P., and Lovett M.A. Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high dose ciprofloxacin. Clin Infect Dis 25 (1997) 936-937
80. Krcmery Jr. V., Filka J., Uher J., et al. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diagn Microbiol Infect Dis 35 (1999) 75-80
81. Saez-Llorens X., McCoig C., Feris J.M., et al. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 21 (2002) 14-22
82. Shapiro M.A., Donovan K.D., and Gage J.W. Comparative therapeutic efficacy of clinafloxacin in a pneumococcal meningitis mouse model. J Antimicrob Chemother 45 (2000) 489-492
83. Smirnov A., Wellmer A., Gerber J., et al. Gemifloxacin is effective in experimental pneumococcal meningitis. Antimicrob Agents Chemother 44 (2000) 767-770
84. Cottagnoud P., Acosta F., Cottagnoud M., et al. Gemifloxacin is efficacious against penicillin-resistant and quinolone resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 46 (2002) 1607-1609
85. Schmidt H., Dalhoff A., Steurtz K., et al. Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother 42 (1998) 1397-1401
86. Ostergaard C., Sorensen T.K., Knudsen J.D., et al. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother 42 (1998) 1706-1712
87. Tarasi A., Capone A., Tarasi D., et al. Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis. J Antimicrob Chemother 43 (1999) 833-835
88. Lutsar I., Friedland I.R., Jafri H.S., et al. Efficacy of gatifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother 43 (1999) 1805-1807
89. Perrig M., Acosta F., Cottagnoud M., et al. Efficacy of gatifloxacin alone and in combination with cefepime against penicillin-resistant Streptococcus pneumoniae in a rabbit meningitis model and in vitro. J Antimicrob Chemother 47 (2001) 701-704
90. Rodriguez-Cerrato V., Ghaffar F., Saavedra J., et al. BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 45 (2001) 3098-3103
91. Cottagnoud P., Acosta F., Cottagnoud M., et al. Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 46 (2002) 184-187
92. Rodriguez-Cerrato V., McCoig C.C., Saavedra J., et al. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob Agents Chemother 47 (2003) 211-215
93. Sipahi O.R., Turhan T., Pullukcu H., et al. Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis. J Antimicrob Chemother 61 (2008) 670-673
94. Kanellakopoulou K., Pagoulatou A., Stroumpoulis K., et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid in humans: implication for a bactericidal effect. J Antimicrob Chemother 61 (2008) 1328-1331
95. Cottagnoud P., Cottagnoud M., Acosta F., et al. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. Eur J Clin Microbiol Infect Dis 22 (2003) 656-662
96. Steenbergen J., Alder J., Thorne G.M., et al. Daptomycin: a lipopeptide for the treatment of serious gram-positive infections. J Antimicrob Chemother 55 (2005) 283-288
97. Cottagnoud P., Pfister M., Acosta F., et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 48 (2004) 3928-3933
98. Gerber P., Stucki A., Acosta F., et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 57 (2006) 720-723
99. 3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall. Antimicrob Agents Chemother 51 (2007) 2249-2252
100. Grandgirard D., Schurch C., Cottagnoud P., et al. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 51 (2007) 2173-2178
101. Lee D.H., Palermo B., and Chowdhury M. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 47 (2008) 588-590
102. Jones R.N., Ross J.E., Castanheira M., et al. United States resistance surveillance results for linezolid (LEADER program for 2007). Diagn Microbiol Infect Dis 62 (2008) 416-426
103. Ntziora F., and Falagas M.E. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 41 (2007) 296-308
104. Cottagnoud P., Gerber C.M., Acosta F., et al. Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 46 (2000) 981-985
105. Attwood R.J., and LaPlante K.L. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64 (2007) 2335-2348
106. Stucki A., Gerber P., Acosta F., et al. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 50 (2006) 770-773